Cisplatin Polylactic Acid Nanoparticles Combined with miR-181a Alleviates the Growth, Migration and Apoptosis of PG Cells in Lung Cancer Rats

Abstract

In this experiment, cisplatin-polylactic acid nanoparticles (CPAN) were used to intervene in a rat model of lung cancer, to assess the effects and mechanism of combined miR-181a on lung cancer using Human giant cell lung cancer cell line (PG) cells. CPAN were prepared and lung cancer rat model was constructed. Rats were then grouped into healthy group, lung cancer group, cisplatin group, CPAN group, and CPAN+miR-181a agonist group, with 4 rats in each group. Expressions of PTEN induced putative kinase 1 (PINK1) and Parkin were analyzed, followed by cell proliferation, apoptosis, and migration, and also relationship between miR-181a and Parkin. The CPAN were successfully prepared and the rat model of lung cancer was established. CPAN improved the lung function of rats with lung cancer and this was related to overexpression of miR-181a. The number of inflammatory cells in lung tissue decreased in the cisplatin-poly lactic acid (PLA) nanoparticle group, and epithelial edema of bronchial mucosa was alleviated when compared to the lung cancer group. PINK1/Parkin protein expression was lower than that in the lung cancer group, and proliferation of PG cells decreased with increased apoptosis, and decreased migration inhibition. Intervention of CPAN combined with miR-181a can down-regulate PINK1/Parkin, improving lung function of lung cancer rats, inhibiting proliferation and migration, and promoting apoptosis.